Physician profile
William Halford
NPI 1699734798
$5,334.63
in general payments reported to CMS, 2019-2025
35 companies · $611 in 2025
The $611 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $607 · 2021: $691 · 2022: $1,122 · 2023: $844 · 2024: $842 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,296.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,073.10 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $823.16 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $678.08 | 2022 | |
| Abbvie INC. | $292.59 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.59 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $253.18 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $252.60 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $244.36 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $242.08 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $178.66 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $161.92 | 2019-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $107.86 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $100.26 | 2019-2025 | Gardasil 9, Capvaxive |
| Teva Pharmaceuticals USA, INC. | $68.49 | 2022-2023 | Austedo |
| Exact Sciences Corporation | $52.49 | 2025 | Cologuard Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $48.60 | 2024 | Rexulti, Jynarque |
| Astellas Pharma US INC | $48.03 | 2023-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $47.34 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $41.50 | 2019-2021 | |
| Eisai INC. | $39.34 | 2021-2023 | |
| Ibsa Pharma INC. | $38.86 | 2021-2023 | Tirosint, Licart |
| Allergan, INC. | $33.95 | 2020 | |
| Currax Pharmaceuticals LLC | $30.25 | 2025 | Contrave |
| Neurocrine Biosciences, INC. | $28.09 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.84 | 2023 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $22.50 | 2025 | Unithroid |
| Boston Scientific Corporation | $20.34 | 2022 | |
| Dermira, INC. | $19.66 | 2020 | |
| Dexcom, INC. | $17.56 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.08 | 2024 | Voquezna |
| Medtronic, INC. | $16.51 | 2023 | Inpen Smart Insulin Delivery System |
| Sanofi-Aventis U.S. LLC | $15.46 | 2021 | |
| Esperion Therapeutics, INC. | $14.61 | 2020 | |
| Ethicon US, LLC | $12.82 | 2020 | |
| Genentech USA, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Halford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.